Page last updated: 2024-11-13

ls-102

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID Source	ID
PubMed CID	118518043
SCHEMBL ID	17265617
MeSH ID	M0585032

Synonyms (11)

Synonym
LS-102 ,
SCHEMBL17265617
HY-135844
CS-0114389
6-n-(1,3-benzoxazol-6-yl)-4-n-[(1s)-1-cyclohexylethyl]-2-n-ethyl-2-n-[2-(ethylamino)ethyl]-1,3,5-triazine-2,4,6-triamine
MS-28237
1456891-34-1
(s)-n2-(benzo[d]oxazol-6-yl)-n4-(1-cyclohexylethyl)-n6-ethyl-n6-(2-(ethylamino)ethyl)-1,3,5-triazine-2,4,6-triamine
PD157582
Z4609391014
AKOS040733622

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
"Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability, while the toxic tolerance was similar to previous estimates."	( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102). Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)	1.23

Pharmacokinetics

Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability. The toxic tolerance was similar to previous estimates.

Excerpt	Reference	Relevance
" The objective of this study was to investigate the intestinal absorption, main pharmacokinetic parameters and acute toxicity of LS-102 in rodents compared with AGS IV."	( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102). Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)	0.92
" The plasma concentrations were detected by a validated UHPLC-MS/MS method, and pharmacokinetic parameters were calculated using a compartmental model."	( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102). Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)	0.71
"Oral LS-102 produced a pharmacokinetic profile different from AGS IV with higher bioavailability, while the toxic tolerance was similar to previous estimates."	( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102). Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)	1.23
"The objective of this study was to investigate the pharmacokinetic properties of LS-102 after single-dose, oral administration in beagle dogs by developing and validating an ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method."	( Determination of a astragaloside IV derivative LS-102 in plasma by ultra-performance liquid chromatography-tandem mass spectrometry in dog plasma and its application in a pharmacokinetic study. Cheng, Y; Ding, LS; He, Y; Luo, P; Qing, LS; Sun, WX; Xie, J; Zhang, ZF, 2019)	1

Bioavailability

Excerpt	Reference	Relevance
" However, its disappointing clinical application is mainly caused by its very low solubility in biologic fluids, resulting in poor bioavailability after oral administration."	( Pharmacokinetics Comparison, Intestinal Absorption and Acute Toxicity Assessment of a Novel Water-Soluble Astragaloside IV Derivative (Astragalosidic Acid, LS-102). Chen, L; Chen, TB; Ding, LS; Luo, P; Qing, LS; Sun, WX; Zhang, ZF, 2019)	0.71
" However, it is disappointing that the in vivo solubility of astragaloside IV and its bioavailability after oral administration are very low."	( The Astragaloside IV Derivative LS-102 Ameliorates Obesity-Related Nephropathy. Li, Z; Liu, Y; Luo, P; Wu, J; Yang, W; Yang, Y, 2022)	1

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	4 (80.00)	24.3611
2020's	1 (20.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	29.67 (24.57)
Research Supply Index	1.79 (2.92)
Research Growth Index	4.59 (4.65)
Search Engine Demand Index	57.44 (26.88)
Search Engine Supply Index	3.73 (0.95)

This Compound (29.67)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes
benzoxazoles 1,3-benzoxazole : A benzoxazole in which the benzene ring is fused to a 1,3-oxazole ring across positions 4 and 5.. benzoxazole : Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.	3.26	5	1,3-benzoxazoles; mancude organic heterobicyclic parent
astragaloside a [no description available]	2.94	3
beta-escin [no description available]	2.94	3

Condition	Relationship Strength	Studies
Diabetic Glomerulosclerosis [description not available]	2.41	1
Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.	2.41	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	7.41	1
Diffuse Parenchymal Lung Disease [description not available]	2.11	1
Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.	2.11	1
Rheumatoid Arthritis [description not available]	2.07	1
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	2.07	1

chemdatabank.com